

# João N Moreira

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8831963/publications.pdf>

Version: 2024-02-01

85  
papers

3,231  
citations

136950

32  
h-index

155660

55  
g-index

85  
all docs

85  
docs citations

85  
times ranked

4816  
citing authors

#	ARTICLE	IF	CITATIONS
1	Modelling the impact of nucleolin expression level on the activity of F3 peptide-targeted pH-sensitive pegylated liposomes containing doxorubicin. <i>Drug Delivery and Translational Research</i> , 2022, 12, 629-646.	5.8	6
2	Antagonist G-targeted liposomes for improved delivery of anticancer drugs in small cell lung carcinoma. <i>International Journal of Pharmaceutics</i> , 2022, 612, 121380.	5.2	8
3	Targeted liposomal doxorubicin/ceramides combinations: The importance to assess the nature of drug interaction beyond bulk tumor cells. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 172, 61-77.	4.3	2
4	New advances in exosome-based targeted drug delivery systems. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103628.	4.4	47
5	Nucleolin Overexpression Predicts Patient Prognosis While Providing a Framework for Targeted Therapeutic Intervention in Lung Cancer. <i>Cancers</i> , 2022, 14, 2217.	3.7	7
6	Cancer Stem Cells and Nucleolin as Drivers of Carcinogenesis. <i>Pharmaceutics</i> , 2021, 14, 60.	3.8	31
7	In Vitro and In Vivo Tumor Models for the Evaluation of Anticancer Nanoparticles. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1295, 271-299.	1.6	5
8	Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of inÁvivo studies. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 925-940.	12.0	113
9	GMP-grade nanoparticle targeted to nucleolin downregulates tumor molecular signature, blocking growth and invasion, at low systemic exposure. <i>Nano Today</i> , 2021, 37, 101095.	11.9	15
10	Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 180.	8.6	27
11	The Enhanced Efficacy of Intracellular Delivery of Doxorubicin/C6-Ceramide Combination Mediated by the F3 Peptide/Nucleolin System Is Supported by the Downregulation of the PI3K/Akt Pathway. <i>Cancers</i> , 2021, 13, 3052.	3.7	7
12	In Vitro Studies on Nasal Formulations of Nanostructured Lipid Carriers (NLC) and Solid Lipid Nanoparticles (SLN). <i>Pharmaceutics</i> , 2021, 14, 711.	3.8	37
13	Current challenges and emerging opportunities of CAR-T cell therapies. <i>Journal of Controlled Release</i> , 2020, 319, 246-261.	9.9	78
14	Using the quality by design (QbD) approach to optimize formulations of lipid nanoparticles and nanoemulsions: A review. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 28, 102206.	3.3	44
15	Application of the Quality-by-Design (QbD) Approach to Improve the Nose-to-Brain Delivery of Diazepam-Loaded Nanostructured Lipid Carriers (NLCs). <i>Proceedings (mdpi)</i> , 2020, 78, .	0.2	1
16	Nucleolin-based targeting strategies for cancer therapy: from targeted drug delivery to cytotoxic ligands. <i>Drug Discovery Today</i> , 2019, 24, 1985-2001.	6.4	52
17	Hormones, Blood Products, and Therapeutic Enzymes. <i>Advances in Biochemical Engineering/Biotechnology</i> , 2019, 171, 115-153.	1.1	1
18	Insights on the Formulation of Recombinant Proteins. <i>Advances in Biochemical Engineering/Biotechnology</i> , 2019, 171, 23-54.	1.1	3

#	ARTICLE	IF	CITATIONS
19	Abstract A101: Nucleolin: A novel cell surface protein for neuroblastoma targeted therapy. , 2019, , .		0
20	Meeting the needs of breast cancer: A nucleolin™s perspective. Critical Reviews in Oncology/Hematology, 2018, 125, 89-101.	4.4	32
21	Nanoparticulate vaccine inhibits tumor growth via improved T cell recruitment into melanoma and huHER2 breast cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 835-847.	3.3	17
22	Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer. Pathology and Oncology Research, 2018, 24, 701-716.	1.9	17
23	Moving Liposome Technology from the Bench to the Oncological Patient: Towards Performance-by-Design. AAPS Advances in the Pharmaceutical Sciences Series, 2018, , 171-211.	0.6	0
24	Lipid-Based Nanosystems for the Delivery of siRNA: Challenges and Trends. , 2018, , 495-515.		0
25	Anticancer activity and antibody-dependent cell-mediated cytotoxicity of novel anti-nucleolin antibodies. Scientific Reports, 2018, 8, 7450.	3.3	12
26	Nucleolin is expressed in patient-derived samples and glioblastoma cells, enabling improved intracellular drug delivery and cytotoxicity. Experimental Cell Research, 2018, 370, 68-77.	2.6	24
27	Targeting Cancer Stem Cells and Non-Stem Cancer Cells: The Potential of Lipid- Based Nanoparticles. Current Pharmaceutical Design, 2018, 23, 6563-6572.	1.9	4
28	Rational design of nanoparticles towards targeting antigen-presenting cells and improved T cell priming. Journal of Controlled Release, 2017, 258, 182-195.	9.9	79
29	The cancer stem cell phenotype as a determinant factor of the heterotypic nature of breast tumors. Critical Reviews in Oncology/Hematology, 2017, 113, 111-121.	4.4	30
30	Dual release of a hydrophilic and a hydrophobic osteogenic factor from a single liposome. RSC Advances, 2016, 6, 114599-114612.	3.6	6
31	Safety profile of the intravenous administration of brain-targeted stable nucleic acid lipid particles. Data in Brief, 2016, 6, 700-705.	1.0	11
32	Intravenous administration of brain-targeted stable nucleic acid lipid particles alleviates Machado-Joseph disease neurological phenotype. Biomaterials, 2016, 82, 124-137.	11.4	86
33	Inoculated Cell Density as a Determinant Factor of the Growth Dynamics and Metastatic Efficiency of a Breast Cancer Murine Model. PLoS ONE, 2016, 11, e0165817.	2.5	31
34	On the use of dexamethasone-loaded liposomes to induce the osteogenic differentiation of human mesenchymal stem cells. Journal of Tissue Engineering and Regenerative Medicine, 2015, 9, 1056-1066.	2.7	33
35	Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination. Biomaterials, 2015, 69, 76-88.	11.4	73
36	Antibacterial activity of chitosan nanofiber meshes with liposomes immobilized releasing gentamicin. Acta Biomaterialia, 2015, 18, 196-205.	8.3	154

#	ARTICLE	IF	CITATIONS
37	Translational Peptide-associated Nanosystems: Promising Role as Cancer Vaccines. <i>Current Topics in Medicinal Chemistry</i> , 2015, 16, 291-313.	2.1	2
38	Bridging cancer biology and the patients' needs with nanotechnology-based approaches. <i>Cancer Treatment Reviews</i> , 2014, 40, 626-635.	7.7	40
39	Immobilization of bioactive factor-loaded liposomes on the surface of electrospun nanofibers targeting tissue engineering. <i>Biomaterials Science</i> , 2014, 2, 1195-1209.	5.4	54
40	Instructive Nanofibrous Scaffold Comprising Runt-Related Transcription Factor 2 Gene Delivery for Bone Tissue Engineering. <i>ACS Nano</i> , 2014, 8, 8082-8094.	14.6	81
41	Development of a Novel Nanoparticle-based Therapeutic Vaccine for Breast Cancer Immunotherapy. <i>Procedia in Vaccinology</i> , 2014, 8, 62-67.	0.4	6
42	Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination. <i>Journal of Controlled Release</i> , 2014, 196, 122-131.	9.9	34
43	Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 1417-1438.	5.4	25
44	Abstract 3003: Targeting nucleolin: A potential strategy to overcome stroma-mediated bevacizumab resistance in lung cancer. , 2014, , .		0
45	Tumor-targeted Chlorotoxin-coupled Nanoparticles for Nucleic Acid Delivery to Glioblastoma Cells: A Promising System for Glioblastoma Treatment. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e100.	5.1	83
46	MRI Tracking of Macrophages Labeled with Glucan Particles Entrapping a Water Insoluble Paramagnetic Gd-Based Agent. <i>Molecular Imaging and Biology</i> , 2013, 15, 307-315.	2.6	16
47	Efficient intracellular delivery of siRNA with a safe multitargeted lipid-based nanoplatform. <i>Nanomedicine</i> , 2013, 8, 1397-1413.	3.3	23
48	Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 85, 356-364.	4.3	27
49	Impact of PLK-1 Silencing on Endothelial Cells and Cancer Cells of Diverse Histological Origin. <i>Current Gene Therapy</i> , 2013, 13, 189-201.	2.0	7
50	Development, Characterization and <i>In Vitro</i> Evaluation of Single or Co-Loaded Imatinib Mesylate Liposomal Formulations. <i>Journal of Nanoscience and Nanotechnology</i> , 2012, 12, 2891-2900.	0.9	2
51	Nature-inspired particles as carriers for multimodal molecular imaging applications. , 2012, , .		0
52	Lipid-Based Nanoparticles for siRNA Delivery in Cancer Therapy: Paradigms and Challenges. <i>Accounts of Chemical Research</i> , 2012, 45, 1163-1171.	15.6	199
53	Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 61-73.	2.5	54
54	Toward a siRNA-containing nanoparticle targeted to breast cancer cells and the tumor microenvironment. <i>International Journal of Pharmaceutics</i> , 2012, 434, 9-19.	5.2	45

#	ARTICLE	IF	CITATIONS
55	Yeast cell wall particles: a promising class of nature-inspired microcarriers for multimodal imaging. <i>Chemical Communications</i> , 2011, 47, 10635.	4.1	31
56	Selective Cytotoxicity of Oxysterols through Structural Modulation on Rings A and B. Synthesis, in Vitro Evaluation, and SAR. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 6375-6393.	6.4	46
57	Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 275-284.	2.3	17
58	Supramolecular protamine/Gd-loaded liposomes adducts as relaxometric protease responsive probes. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 1131-1135.	3.0	14
59	Liposomal imatinib+mitoxantrone combination: Formulation development and therapeutic evaluation in an animal model of prostate cancer. <i>Prostate</i> , 2011, 71, 81-90.	2.3	31
60	Abstract 4444: Targeted delivery of siRNAs to tumor cells and the tumor microenvironment. , 2011, , .		0
61	Abstract C233: Limiting tumor invasion with multifunctional nanoparticle targeting the tumor microenvironment.. , 2011, , .		0
62	Co-encapsulation of anti-BCR-ABL siRNA and imatinib mesylate in transferrin receptor-targeted sterically stabilized liposomes for chronic myeloid leukemia treatment. <i>Biotechnology and Bioengineering</i> , 2010, 107, 884-893.	3.3	47
63	Synthesis and structure-activity relationship study of novel cytotoxic carbamate and N-acylheterocyclic bearing derivatives of betulin and betulinic acid. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 4385-4396.	3.0	63
64	In vitro modulation of Bcl-2 levels in small cell lung cancer cells: effects on cell viability. <i>Brazilian Journal of Medical and Biological Research</i> , 2010, 43, 1001-1009.	1.5	6
65	Sterols as Anticancer Agents: Synthesis of Ring-B Oxygenated Steroids, Cytotoxic Profile, and Comprehensive SAR Analysis. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 7632-7638.	6.4	64
66	Transferrin Receptor-Targeted Liposomes Encapsulating anti-BCR-ABL siRNA or asODN for Chronic Myeloid Leukemia Treatment. <i>Bioconjugate Chemistry</i> , 2010, 21, 157-168.	3.6	82
67	Design of peptide-targeted liposomes containing nucleic acids. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2010, 1798, 433-441.	2.6	36
68	Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 445-454.	2.3	26
69	Efficient Chemoenzymatic Synthesis, Cytotoxic Evaluation, and SAR of Epoxysterols. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4007-4019.	6.4	30
70	Chapter 14 Targeted Lipoplexes for siRNA Delivery. <i>Methods in Enzymology</i> , 2009, 465, 267-287.	1.0	14
71	Abstract A129: Targeted delivery of therapeutics to tumor cells and the tumor microenvironment. , 2009, , .		1
72	Simultaneous evaluation of viability and Bcl-2 in small cell lung cancer. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2008, 73A, 1165-1172.	1.5	10

#	ARTICLE	IF	CITATIONS
73	Synthesis and Photoluminescence of ZnS Quantum Dots. Journal of Nanoscience and Nanotechnology, 2008, 8, 1312-1315.	0.9	39
74	Bcl-2-Targeted Antisense Therapy (Oblimersen Sodium): Towards Clinical Reality. Reviews on Recent Clinical Trials, 2006, 1, 217-235.	0.8	47
75	Targeting of sterically stabilised pH-sensitive liposomes to human T-leukaemia cells. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 59, 359-366.	4.3	49
76	Antagonist G-mediated targeting and cytotoxicity of liposomal doxorubicin in NCI-H82 variant small cell lung cancer. Brazilian Journal of Medical and Biological Research, 2004, 37, 1185-1192.	1.5	9
77	On the formulation of pH-sensitive liposomes with long circulation times. Advanced Drug Delivery Reviews, 2004, 56, 947-965.	13.7	440
78	Technology evaluation: LErafAON, NeoPharm. Current Opinion in Molecular Therapeutics, 2003, 5, 547-52.	2.8	4
79	ADVENTURES IN TARGETING. Journal of Liposome Research, 2002, 12, 5-12.	3.3	56
80	Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity. Pharmaceutical Research, 2002, 19, 265-269.	3.5	127
81	A growth factor antagonist as a targeting agent for sterically stabilized liposomes in human small cell lung cancer. Biochimica Et Biophysica Acta - Biomembranes, 2001, 1514, 303-317.	2.6	40
82	Targeting Stealth liposomes in a murine model of human small cell lung cancer. Biochimica Et Biophysica Acta - Biomembranes, 2001, 1515, 167-176.	2.6	88
83	Carboplatin liposomes coated with O-palmitoylpullulan: In vitro characterization. International Journal of Pharmaceutics, 1997, 147, 153-164.	5.2	12
84	Evaluation of in vitro stability of large unilamellar liposomes coated with a modified polysaccharide (O-palmitoylpullulan). Journal of Materials Science: Materials in Medicine, 1996, 7, 301-303.	3.6	11
85	Quimioterapia combinada no tratamento do cancro: princípios e estratégias nanotecnológicas de entrega de fármacos. , 0, , 675-700.		0